DMK Pharmaceuticals Corporation
CY3B
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 68.45% | -2.11% | 13.63% | 62.08% | 64.41% |
| Total Depreciation and Amortization | -83.16% | -76.30% | -68.19% | 2.23% | 6.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,975.98% | 550.45% | 240.51% | 10.69% | -99.10% |
| Change in Net Operating Assets | 63.02% | 281.06% | 111.70% | -30.20% | 16.82% |
| Cash from Operations | 50.16% | 74.04% | 77.85% | 77.48% | 23.00% |
| Capital Expenditure | -- | -- | -- | 59.73% | -39.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 190.57% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 79.07% | -99.84% | -46.02% | -24,700.65% | 762.01% |
| Cash from Investing | 126.82% | -86.40% | -45.08% | -86.67% | 2,352.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 99.56% | -- |
| Cash from Financing | 2,694.18% | -- | -- | 100.00% | 114.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 100.00% | -118.12% | -- | -- | -107.06% |
| Net Change in Cash | 192.84% | 72.34% | 137.02% | 75.71% | 43.70% |